The company provides a direct‑to‑consumer saliva kit that generates FDA‑cleared genotyping reports on ancestry, health risks, carrier status and pharmacogenetics, delivered through a secure online portal. Customers can subscribe for continuous report updates and access optional exome sequencing or clinical blood tests via a telehealth workflow, with data stored using end‑to‑end encryption.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Many adults lack convenient, affordable access to comprehensive genetic information that can inform health decisions, ancestry understanding, and family planning, because traditional testing requires clinic visits, referrals, and costly laboratory services.
Solution
The company offers a direct‑to‑consumer saliva‑based genotyping kit that can be ordered online and returned by mail. After laboratory processing, customers receive a secure online dashboard with personalized reports covering ancestry composition (over 4,500 geographic regions), FDA‑cleared genetic health risk assessments, carrier status for recessive conditions, and pharmacogenetic insights. A subscription service provides continuous updates as new science‑backed reports become available, allowing users to track emerging health insights without additional kits. All data are stored with end‑to‑end encryption and privacy‑by‑design controls, and participants can opt into a research program that contributes de‑identified data to large‑scale genetics studies. The platform also offers optional exome sequencing and clinical blood testing through a telehealth workflow for eligible customers.
Target Audience
The primary customers are health‑conscious adults (18+) who want personal insights into their ancestry, disease risk, carrier status, and medication response, as well as individuals planning families or seeking proactive health management tools.
Features
- Saliva collection kit with qualitative genotyping of clinically relevant variants across the genome
- FDA‑cleared reports for 95+ genetic health risks, carrier status, and pharmacogenetics (CYP2C19, DPYD, SLCO1B1)
- Ancestry analysis spanning 4,500+ reference regions and DNA‑relative matching to identify genetic relatives
- Secure web portal delivering interactive reports, risk visualizations, and actionable health recommendations
- Subscription tier (23andMe+ Premium/Total Health) that unlocks >100 ongoing insights and annual report updates
- Privacy‑by‑design architecture with encrypted data storage, role‑based access, and transparent consent options
- Optional exome sequencing and clinical blood testing performed in CLIA‑ and CAP‑accredited labs via telehealth integration
- Participation in a voluntary research program that aggregates de‑identified data to accelerate genetic discovery